Circulating circRNA in Acute Ischemic Stroke
CRAST
Clinical Significance of Circulating circRNA in Acute Ischemic Stroke (CRAST)
1 other identifier
observational
500
1 country
1
Brief Summary
CRAST is to analyze the expression pattern of circular RNA (circRNA) by bioinformatics analysis in patients with acute ischemic stroke and healthy control. The candidate circRNA will be verified as biomarkers for the detection and prognosis of acute ischemic stroke.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2020
CompletedFirst Submitted
Initial submission to the registry
October 17, 2021
CompletedFirst Posted
Study publicly available on registry
October 28, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
October 30, 2024
CompletedAugust 6, 2024
August 1, 2024
4.1 years
October 17, 2021
August 4, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Differential expression pattern of circRNA
Differential expression pattern of circular RNA (circRNA) will be compared between AIS group and HC group, thus candidate circRNA will be verified as biomarkers for the detection and prognosis of AIS.
90 days
Secondary Outcomes (4)
Dynamic changes of circRNA during the follow-up period
90 days
Correlation of circRNA and stroke-associated infection
30 days
Correlation of circRNA and inflammatory factors in acute ischemic stroke
7 days
Prognostic value of circRNA in acute ischemic stroke
90 days
Study Arms (2)
AIS group
This group includes patients with acute ischemic stroke (AIS).
HC group
This group includes healthy controls (HC).
Interventions
Quantitative Real-time polymerase chain reaction of circular RNA (circRNA).
Eligibility Criteria
There will be 100 patients suspected of AIS (such as transient ischemic attack), 300 AIS patients and 100 Healthy controls，whose data will be applied for construction and validation of diagnostic and predictive models of circRNA from the circulating blood.
You may qualify if:
- Aged 18 years or older
- Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan
- Within 72 hours of symptom onset
- Good performance status
- Signed an approved informed consents
You may not qualify if:
- a history of hemorrhagic infarction, chronic kidney/liver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Neurology
Xuzhou, Jiangsu, China
Biospecimen
An 10 ml peripheral venous blood will be collected from the participants before and after interventions (i.e. intravenous thrombolysis and/or endovascular therapy)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Target Duration
- 90 Days
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 17, 2021
First Posted
October 28, 2021
Study Start
October 1, 2020
Primary Completion
October 30, 2024
Study Completion
October 30, 2024
Last Updated
August 6, 2024
Record last verified: 2024-08
Data Sharing
- IPD Sharing
- Will not share